Bioactive glasses as carriers for bioactive molecules and therapeutic drugs: A review

Journal of Materials Science: Materials in Medicine

Volumn 23, Issue 10, 2012, Pages 2317-2333

  Hum, Jasmin ^a   Boccaccini, Aldo R ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; BIOACTIVE MOLECULES; BONE SUBSTITUTES; BONE TISSUE ENGINEERING; BONE TISSUE SCAFFOLDS; CHEMICAL COMPOSITIONS; CONTROLLED RELEASE; DISSOLUTION PRODUCTS; DRUG DELIVERY SYSTEM; GROWTH FACTOR; HARD TISSUES; OSTEOBLASTIC DIFFERENTIATION; OSTEOCONDUCTIVITY; OSTEOGENIC; RESEARCH EFFORTS; THERAPEUTIC DRUGS;

BIOACTIVITY; BIOCOMPATIBILITY; BIODEGRADATION; BONE; DRUG DELIVERY; GENE EXPRESSION; MEDICAL APPLICATIONS; SCAFFOLDS (BIOLOGY); TISSUE;

BIOACTIVE GLASS;

ANTIBIOTIC AGENT; BIOACTIVE GLASS; BIOMATERIAL; BORIC ACID; CHITOSAN; CORTISONE; DEXAMETHASONE; GENTAMICIN; GLASS; GROWTH FACTOR; HORMONE; HYDROCORTISONE; METOCLOPRAMIDE; PEPTIDE; TETRACYCLINE; TISSUE SCAFFOLD; UNCLASSIFIED DRUG; VANCOMYCIN;

ANGIOGENESIS; BIOCOMPATIBILITY; BIODEGRADABILITY; BONE PROSTHESIS; BONE TISSUE ENGINEERING; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; ENCAPSULATION; GENE EXPRESSION; MOLECULE; PRIORITY JOURNAL; SOFT TISSUE; TISSUE DIFFERENTIATION; TISSUE ENGINEERING; TISSUES;

BIOCOMPATIBLE MATERIALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLASS; HUMANS;

EID: 84867403521     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-012-4580-z     Document Type: Conference Paper

References (129)

1. Brydone AS, Meek D, Maclaine S. Bone grafting, orthopaedic biomaterials, and the clinical need for bone engineering. Proceedings of the institution of mechanical engineers. Part H J Eng Med. 2010;224(12):1329-43.
2. Hing KA. Bone repair in the twenty-first century: biology, chemistry or engineering? Philos Trans Ser A Math Phys Eng Sci. 2004;362(1825):2821-50.
3. Oh S, Oh N, Appleford M, Ong JL. Bioceramics for tissue engineering applications-a review. Am J Biochem Biotechnol. 2006;2(2):49-56.
4. Kellomäki M, Niiranen H, Puumanen K, Ashammakhi N, Waris T, Törmälä P. Bioabsorbable scaffolds for guided bone regeneration and generation. Biomaterials. 2000;21(24):2495-505.
5. O'Keefe RJ, Mao J. Bone tissue engineering and regeneration: from discovery to the clinic-an overview. Tissue Eng Part B Rev. 2011;17(6):389-92.
6. Hench LL, Splinter RJ, Allen WC, Greenlee TK. Bonding mechanism at the interface of ceramic prosthetic materials. J Biomed Mater Res. 1971;5(6):117-41.
7. Davies JE. Bone bonding at natural and biomaterial surfaces. Biomaterials. 2007;28(34):5058-67.
8. Puleo DA, Nanci A. Understanding and controlling the bone-implant interface. Biomaterials. 1999;20(23-24):2311-21.
9. Vallet-Regí M, Ragel CV, Salinas AJ. Glasses with medical applications. Eur J Inorg Chem. 2003;2003(6):1029-42.
10. Hench LL. Bioceramics. J Am Ceram Soc. 1998;81(7):1705-28.
11. ®- derived glass-ceramic scaffolds for bone tissue engineering. Biomaterials. 2006;27(11):2414-25.
12. Hoppe A, Güldal NS, Boccaccini AR. A review of the biological response to ionic dissolution products from bioactive glasses and glass-ceramics. Biomaterials. 2011;32(11):2757-74.
13. Liang W, Rahaman MN, Day DE, Marion NW, Riley GC, Mao JJ. Bioactive borate glass scaffold for bone tissue engineering. J Non-Cryst Solids. 2008;354(15-16):1690-6.
14. 2O system) ions. Acta Biomater. 2009;5(9):3536-47.
15. Fu H, Fu Q, Zhou N, Huang W, Rahaman MN, Wang D, Liu X. In vitro evaluation of borate-based bioactive glass scaffolds prepared by a polymer foam replication method. Mater Sci Eng C. 2009;29(7):2275-81.
16. Day RM, Boccaccini AR, Shurey S, Roether JA, Forbes A, Hench LL, Gabe SM. Assessment of polyglycolic acid mesh and bioactive glass for soft-tissue engineering scaffolds. Biomaterials. 2004;25(27):5857-66.
17. Day RM. Bioactive glass stimulates the secretion of angiogenic growth factors and angiogenesis in vitro. Tissue Eng. 2005;11(5-6):768-77.
18. Gorustovich AA, Roether JA, Boccaccini AR. Effect of bioactive glasses on angiogenesis: a review of in vitro and in vivo evidences. Tissue Eng Part B Rev. 2009;16(2):199-207.
19. Leu A, Stieger SM, Dayton P, Ferrara KW, Leach JK. Angiogenic response to bioactive glass promotes bone healing in an irradiated calvarial defect. Tissue Eng Part A. 2009;15(4):877-85.
20. San Miguel B, Kriauciunas R, Tosatti S, Ehrbar M, Ghayor C, Textor M, Weber FE. Enhanced osteoblastic activity and bone regeneration using surface-modified porous bioactive glass scaffolds. J Biomed Mater Res Part A. 2010;94 A (4): 1023-33.
21. Xynos ID, Edgar AJ, Buttery LDK, Hench LL, Polak JM. Ionic products of bioactive glass dissolution increase proliferation of human osteoblasts and induce insulin-like growth factor II mRNA expression and protein synthesis. Biochem Biophys Res Commun. 2000;276(2):461-5.
22. Hench LL, Polak JM. Third-generation biomedical materials. Science. 2002;295(5557):1014-7.
23. Xynos ID, Edgar AJ, Buttery LDK, Hench LL, Polak JM. Geneexpression profiling of human osteoblasts following treatment with the ionic products of Bioglass-45S5 dissolution. J Biomed Mater Res. 2001;55(2):151-7.
24. Zhang D, Leppäranta O, Munukka E, Ylänen H, Viljanen MK, Eerola E, Hupa M, Hupa L. Antibacterial effects and dissolution behavior of six bioactive glasses. J Biomed Mater Res Part A. 2010;93 A (2): 475-83.
25. Allan I, Newman H, Wilson M. Antibacterial activity of particulate bioglass against supra-and subgingival bacteria. Biomaterials. 2001;22(12):1683-7.
26. Oonishi H, Kushitani S, Yasukawa E, Iwaki H, Hench LL, Wilson J, Tsuji E, Sugihara T. Particulate bioglass compared with hydroxyapatite as a bone graft substitute. Clin Orthop Relat Res. 1997;334:316-25.
27. Oonishi H, Hench LL, Wilson J, Sugihara F, Tsuji E, Matsuura M, Kin S, Yamamoto T, Mizokawa S. Quantitative comparison of bone growth behavior in granules of Bioglass-, A-W glass-ceramic, and hydroxyapatite. J Biomed Mater Res. 2000;51(1):37-46.
28. Li R, Clark AE, Hench LL. An investigation of bioactive glass powders by sol-gel processing. J Appl Biomater. 1991;2(4):231-9.
29. Li N, Jie Q, Zhu S, Wang R. Preparation and characterization of macroporous sol-gel bioglass. Ceram Int. 2005;31(5):641-6.
30. Balamurugan A, Sockalingum G, Michel J, Fauré J, Banchet V, Wortham L, Bouthors S, Laurent-Maquin D, Balossier G. Synthesis and characterisation of sol gel derived bioactive glass for biomedical applications. Mater Lett. 2006;60(29-30):3752-7.
31. Mouriño V, Boccaccini AR. Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds. J Roy Soc. 2010;7(43):209-27.
32. Monsigny M, Roche A-C, Midoux P, Mayer R. Glycoconjugates as carriers for specific delivery of therapeutic drugs and genes. Adv Drug Deliv Rev. 1994;14(1):1-24.
33. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-22.
34. Arcos D, Vallet-Regí M. Sol-gel silica-based biomaterials and bone tissue regeneration. Acta Biomater. 2010;6(8):2874-88.
35. Tö lli H, Kujala S, Levonen K, Jämsä T, Jalovaara P. Bioglass as a carrier for reindeer bone protein extract in the healing of rat femur defect. J Mater Sci Mater Med. 2010;21(5):1677-84.
36. Hutmacher DW. Scaffolds in tissue engineering bone and cartilage. Biomaterials. 2000;21(24):2529-43.
37. Sokolsky-Papkov M, Agashi K, Olaye A, Shakesheff K, Domb AJ. Polymer carriers for drug delivery in tissue engineering. Adv Drug Deliv Rev. 2007;59(4-5):187-206.
38. Wang M. Composite scaffolds for bone tissue engineering. Am J Biochem Biotechnol. 2006;2:80-84.
39. Xia W, Chang J. Well-ordered mesoporous bioactive glasses (MBG): a promising bioactive drug delivery system. J Controlled Release. 2006;110(3):522-30.
40. Colilla M, Izquierdo-Barba I, Vallet-Regí M. Novel biomaterials for drug delivery. Expert Opin Ther Pat. 2008;18(6):639-56.
41. Balas F, Manzano M, Horcajada P, Vallet-Regí M. Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc. 2006;128(25):8116-7.
42. Vallet-Regí M, Rámila A, del Real RP, Pérez-Pariente J. A new property of MCM-41: drug delivery system. Chem Mater. 2001;13(2):308-11.
43. Muñoz B, Rámila A, Pérez-Pariente J, Díaz I, Vallet-Regí M. MCM-41 organic modification as drug delivery rate regulator. Chem Mater. 2003;15(2):500-3.
44. Eiff C, Jansen B, Kohnen W, Becker K. Infections associated with medical devices: pathogenesis, management and prophylaxis. Drugs. 2005;65(2):179-214.
45. Miyai T, Ito A, Tamazawa G, Matsuno T, Sogo Y, Nakamura C, Yamazaki A, Satoh T. Antibiotic-loaded poly-e-caprolactone and porous b-tricalcium phosphate composite for treating osteomyelitis. Biomaterials. 2008;29(3):350-8.
46. Ciampolini J, Harding KG. Pathophysiology of chronic bacterial osteomyelitis. Why do antibiotics fail so often? Postgrad Med J. 2000;76(898):479-83.
47. Schnappinger D, Hillen W. Tetracyclines: antibiotic action, uptake, and resistance mechanisms. Arch Microbiol. 1996;165(6):359-69.
48. Goodson JM, Cugini MA, Kent RL, Armitage GC, Cobb CM, Fine D, Fritz ME, Green E, Imoberdorf MJ, Killoy WJ, Mendieta C, Niederman R, Offenbacher S, Taggart EJ, Tonetti M. Multicenter evaluation of tetracycline fiber therapy: II. Clinical response. J Periodontal Res. 1991;26(4):371-9.
49. Vanderkerckhove BNA, Quirynen M, Van Steenberghe D. The use of tetracycline-containing controlled-release fibers in the treatment of refractory periodontitis. J Periodontol. 1997;68(4):353-61.
50. Domingues ZR, Cortés ME, Gomes TA, Diniz HF, Freitas CS, Gomes JB, Faria AMC, Sinisterra RD. Bioactive glass as a drug delivery system of tetracycline and tetracycline associated with b-cyclodextrin. Biomaterials. 2004;25(2):327-33.
51. Irie T, Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J Pharm Sci. 1997;86(2):147-62.
52. Arun R, Ashok KCK, Sravanthi VVNSS. Cyclodextrins as drug carrier molecule: a review. Sci Pharm. 2008;76:567-98.
53. Uekama K, Otagiri M. Cyclodextrins in drug carrier systems. Crit Rev Ther Drug Carrier Syst. 1987;3(1):1-40.
54. Domingues RZ, Clark AE, Brennan AB. A sol-gel derived bioactive fibrous mesh. J Biomed Mater Res. 2001;55(4):468-74.
55. Andrade AL, Souza DM, Vasconcellos WA, Ferreira RV, Domingues RZ. Tetracycline and/or hydrocortisone incorporation and release by bioactive glasses compounds. J Non-Cryst Solids. 2009;355(13):811-6.
56. Cevc G, Blume G. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta. 2004;1663:61-73.
57. Xie Z, Liu X, Jia W, Zhang C, Huang W, Wang J. Treatment of osteomyelitis and repair of bone defect by degradable bioactive borate glass releasing vancomycin. J Controlled Release. 2009;139(2):118-26.
58. Day DE, White JE, Brown RF, McMenamin KD. Transformation of borate glasses into biologically useful materials. Glass Technol. 2003;44(2):75-81.
59. Yao A, Wang D, Huang W, Fu Q, Rahaman MN, Day DE. In vitro bioactive characteristics of borate-based glasses with controllable degradation behavior. J Am Ceram Soc. 2007;90(1):303-6.
60. Nielsen FH. The emergence of boron as nutritionally important throughout the life cycle. Nutrition. 2000;16(7-8):512-4.
61. Soundrapandian C, Basu D, Sa B, Datta S. Local drug delivery system for the treatment of osteomyelitis: in vitro evaluation. Drug Dev Ind Pharm. 2010;37(5):538-46.
62. Lee K, Silva EA, Mooney DJ. Growth factor delivery-based tissue engineering: general approaches and a review of recent developments. J Roy Soc. 2011;8(55):153-70.
63. Takita H, Vehof JW, Jansen JA, Yamamoto M, Tabata Y, Tamura M, Kuboki Y. Carrier dependent cell differentiation of bone morphogenetic protein-2 induced osteogenesis and chondrogenesis during the early implantation stage in rats. J Biomed Mater Res A. 2004;71(1):181-9.
64. Välimäki W, Yrjans JJ, Vuorio E, Aro HT. Combined effect of BMP-2 gene transfer and bioactive glass microspheres on enhancement of new bone formation. J Biomed Mater Res A. 2005;75(3):501-9.
65. Bergeron E, Marquis ME, Chrétien I, Faucheux N. Differentiation of preosteoblasts using a delivery system with BMPs and bioactive glass microspheres. J Mater Sci Mater Med. 2007;18(2):255-63.
66. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22(4):233-41.
67. Xiao YT, Xiang LX, Shao JZ. Bone morphogenetic protein. Biochem Biophys Res Commun. 2007;362(3):550-3.
68. Cheng H, Jiang W, Phillips FM, Haydon RC, Peng Y, Zhou L, Luu HH, An N, Breyer B, Vanichakarn P, Szatkowski JP, Park JY, He TC. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am. 2003;85-A(8):1544-52.
69. Pekkarinen T, Lindholm TS, Hietala O, Jalovaara P. New bone formation induced by injection of native reindeer bone morphogenetic protein extract. Scand J Surg. 2003;92:227-30.
70. Seeherman HJ, Bouxsein M, Kim H, Li R, Li XJ, Aiolova M, Wozney JM. Recombinant human bone morphogenetic protein-2 delivered in an injectable calcium phosphate paste accelerates osteotomy-site healing in a nonhuman primate mode. J Bone Joint Surg Am. 2004;86-A(9):1961-72.
71. Agrawal CM, Best J, Heckman JD, Boyan BD. Protein release kinetics of a biodegradable implant for fracture non-unions. Biomaterials. 1995;16(16):1255-60.
72. Athanasiou KA, Singhal AR, Agrawal CM, Boyan BD. In vitro degradation and release characteristics of biodegradable implants containing trypsin inhibitor. Clin Orthop Relat Res. 1995;315:272-81.
73. Santos EM, Radin S, Ducheyne P. Sol-gel derived carrier for the controlled release of proteins. Biomaterials. 1999;20(19):1695-700.
74. Chen QZ, Ahmed I, Knowles JC, Nazhat SN, Boccaccini AR, Rezwan K. Collagen release kinetics of surface functionalized 45S5 Bioglass-based porous scaffolds. J Biomed Mater Res A. 2008;86(4):987-95.
75. Heule M, Rezwan K, Cavalli L, Gauckler LJ. A miniaturized enzyme reactor based on hierarchically shaped porous ceramic microstruts. Adv Mater. 2003;15(14):1191-4.
76. Williams RA, Blanch HW. Covalent immobilization of protein monolayers for biosensor applications. Biosens Bioelectron. 1994;9(2):159-67.
77. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
78. Yan X, Yu C, Zhou X, Tang J, Zhao D. Highly ordered mesoporous bioactive glasses with superior in vitro bone-forming bioactivities. Angewandte Chemie Internationale Edition. 2004;43(44):5980-4.
79. Wu C, Ramaswamy Y, Zhu Y, Zheng R, Appleyard R, Howard A, Zreiqat H. The effect of mesoporous bioactive glass on the physiochemical, biological and drug-release properties of poly (DL-lactide-co-glycolide) films. Biomaterials. 2009;30(12):2199-208.
80. Wu C, Zhang Y, Zhou Y, Fan W, Xiao Y. A comparative study of mesoporous-glass/silk and non-mesoporous-glass/silk scaffolds: physiochemistry and in vivo osteogenesis. Acta Biomater. 2011;7(5):2229-36.
81. Horcajada P, Rámila A, Boulahya K, González-Calbet J, Vallet-Regí M. Bioactivity in ordered mesoporous materials. Solid State Sci. 2004;6(11):1295-300.
82. López-Noriega A, Arcos D, Izquierdo-Barba I, Sakamoto Y, Terasaki O, Valllet-Regí M. Ordered mesoporous bioactive glasses for bone tissue regeneration. Chem Mater. 2006;18(13):3137-44.
83. Sun J, Li Y, Li L, Zhao W, Li L, Gao J, Ruan M, Shi J. Functionalization and bioactivity in vitro of mesoporous bioactive glasses. J Non-Cryst Solids. 2008;354(32):3799-805.
84. Xue JM, Shi M. PLGA/mesoporous silica hybrid structure for controlled drug release. J Controlled Release. 2004;98(2):209-17.
85. Sampath SS, Robinson DH. Comparison of new and existing spectrophotometric methods for the analysis of tobramycin and other aminoglycosides. J Pharm Sci. 1990;79(5):428-31.
86. Zhang X, Wyss UP, Pichora D, Goosen MFA. A mechanistic study of antibiotic release from biodegradable poly (D, L-lactide) cylinders. J Controlled Release. 1994;31(2):129-44.
87. Kim H-W, Kim H-E, Knowles JC. Production and potential of bioactive glass nanofibers as a next-generation biomaterial. Adv Funct Mater. 2006;16(12):1529-35.
88. Xia W, Zhang D, Chang J. Fabrication and in vitro biomineralization of bioactive glass (BG) nanofibres. Nanotechnology. 2007;18(13):135601.
89. Hong Y, Chen X, Jing X, Fan H, Gu Z, Zhang X. Fabrication and drug delivery of ultrathin mesoporous bioactive glass hollow fibers. Adv Funct Mater. 2010;20(9):1503-10.
90. Zhao YF, Loo SCJ, Chen YZ, Boey FYC, Ma J. In situ SAXRD study of sol-gel induced well-ordered mesoporous bioglasses for drug delivery. J Biomed Mater Res Part A. 2007;85 A (4): 1032-42.
91. Laczka M, Cholewa-Kowalska K, Laczka-Osyczka A, Tworzydlo M, Turyna B. Gel-derived materials of a CaO-P (2) O (5) - SiO (2) system modified by boron, sodium, magnesium, aluminum, and fluorine compounds. J Biomed Mater Res. 2000;52(4):601-12.
92. Wu C, Miron R, Sculean A, Kaskel S, Doert T, Schulze R, Zhang Y. Proliferation, differentiation and gene expression of osteoblasts in boron-containing associated with dexamethasone deliver from mesoporous bioactive glass scaffolds. Biomaterials. 2011;32:7068-78.
93. Wu C, Zhang Y, Zhu Y, Friis T, Xiao Y. Structure-property relationships of silk-modified mesoporous bioglass scaffolds. Biomaterials. 2010;31(13):3429-38.
94. Beresford JN, Joyner CJ, Devlin C, Triffitt JT. The effects of dexamethasone and 1, 25-dihydroxyvitamin D3 on osteogenic differentiation of human marrow stromal cells in vitro. Arch Oral Biol. 1994;39(11):941-7.
95. Wu C, Fan W, Gelinsky M, Xiao Y, Simon P, Schulze R, Doert T, Luo Y, Cuniberti G. Bioactive SrO-SiO2 glass with wellordered mesopores: characterization, physiochemistry and biological properties. Acta Biomater. 2011;7(4):1797-806.
96. Zhao D, Feng J, Huo Q, Melosh N, Fredrickson GH, Chmelka BF, Stucky GS. Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores. Science. 1998;279(5350):548-52.
97. Barrias CC, Ribeiro CC, Lamghari M, Miranda CS, Barbosa MA. Proliferation, activity, and osteogenic differentiation of bone marrow stromal cells cultured on calcium titanium phosphate microspheres. J Biomed Mater Res Part A. 2005;72 A (1): 57-66.
98. Kang S-W, Yang HS, Seo S-W, Han DK, Kim B-S. Apatitecoated poly (lactic-co-glycolic acid) microspheres as an injectable scaffold for bone tissue engineering. J Biomed Mater Res Part A. 2008;85 A (3): 747-56.
99. Wu C, Zhang Y, Ke X, Xie Y, Zhu H, Crawford R, Xiao Y. Bioactive mesopore-glass microspheres with controllable proteindelivery properties by biomimetic surface modification. J Biomed Mater Res Part A. 2010;95 A (2): 476-85.
100. Zhu Y, Wu C, Ramaswamy Y, Kockrick E, Simon P, Kaskel S, Zreiqat H. Preparation, characterization and in vitro bioactivity of mesoporous bioactive glasses (MBGs) scaffolds for bone tissue engineering. Microporous Mesoporous Mater. 2008;112(1-3):494-503.
101. He XM, Carter DC. Atomic structure and chemistry of human serum albumin. Nature. 1992;358(6383):209-15.
102. Liu Y, Layrolle P, de Bruijn J, van Blitterswijk C, de Groot K. Biomimetic coprecipitation of calcium phosphate and bovine serum albumin on titanium alloy. J Biomed Mater Res. 2001;57(3):327-35.
103. Hench LL, Thompson I. Twenty-first century challenges for biomaterials. J Roy Soc. 2010;7(4):379-91.
104. Rahaman MN, Day DE, Bal BS, Fu Q, Jung SB, Bonewald LF, Tomsia AP. Bioactive glass in tissue engineering. Acta Biomater. 2011;7(6):2355-73.
105. Yu X, Cai S, Zhang Z, Guohua X. Bioactive pyrophosphate glass/beta-tricalcium phosphate composite with high mechanical properties. Mater Sci Eng C. 2008;28(7):1138-43.
106. Rezwan K, Chen QZ, Blaker JJ, Boccaccini AR. Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering. Biomaterials. 2006;27(18):3413-31.
107. Boccaccini AR, Erol M, Stark WJ, Mohn D, Hong Z, Mano JF. Polymer/bioactive glass nanocomposites for biomedical applications: a review. Comp Sci Technol. 2010;70(13):1764-76.
108. Li X, Shi J, Dong X, Zhang L, Zeng H. A mesoporous bioactive glass/polycaprolactone composite scaffold and its bioactivity behavior. J Biomed Mater Res Part A. 2008;84(1):84-91.
109. Wei J, Chen F, Shin J-W, Hong H, Dai C, Su J, Liu C. Preparation and characterization of bioactive mesoporous wollastonite-polycaprolactone composite scaffold. Biomaterials. 2009;30(6):1080-8.
110. Prabaharan M. Chitosan derivatives as promising materials for controlled drug delivery. J Biomater Appl. 2008;23(1):5-36.
111. Kim I-Y, Seo S-J, Moon H-S, Yoo M-K, Park I-Y, Kim B-C, Cho C-S. Chitosan and its derivatives for tissue engineering applications. Biotechnol Adv. 2008;26(1):1-21.
112. Cevher E, Orhan Z, Mülazimoǧlu L, Sensoy D, Alper M, Yildiz A, Ozsoy Y. Characterization of biodegradable chitosan microspheres containing vancomycin and treatment of experimental osteomyelitis caused by methicillin-resistant Staphylococcus aureus with prepared microspheres. Int J Pharm. 2006;317(2):127-35.
113. Phaechamud T, Charoenteeraboon J. Antibacterial activity and drug release of chitosan sponge containing doxycycline hyclate. AAPS PharmSciTech. 2008;9(3):829-35.
114. Jia W-T, Zhang X, Luo S-H, Liu X, Huang W-H, Rahaman MN, Day DE, Zhang C-Q, Xie Z-P, Wang J-Q. Novel borate glass/chitosan composite as a delivery vehicle for teicoplanin in the treatment of chronic osteomyelitis. Acta Biomater. 2010;6(3):812-9.
115. McCann SJ, White LO, Keevil B. Assay of teicoplanin in serum: comparison of high-performance liquid chromatography and fluorescence polarization immunoassay. J Antimicrob Chemother. 2002;50(1):107-10.
116. Zhu M, Zhang L, He Q, Zhao J, Limin G, Shi J. Mesoporous bioactive glass-coated poly (L-lactic acid) scaffolds: a sustained antibiotic drug release system for bone repairing. J Mater Chem. 2011;21(4):1064-72.
117. Ho MH, Kuo PY, Hsieh HJ, Hsien TY, Hou LT, Lai JY, Wang DM. Preparation of porous scaffolds by using freeze-extraction and freeze-gelation methods. Biomaterials. 2004;25(1):129-38.
118. Boyle VJ, Fancher ME, Ross RW Jr. Rapid, modified Kirby-Bauer susceptibility test with single, high-concentration antimicrobial disks. Antimicrob Agents Chemother. 1973;3(3):418-24.
119. Wahlig H, Dingeldein E, Bergmann R, Reuss K. The release of gentamicin from polymethylmethacrylate beads. An experimental and pharmacokinetic study. J Bone Joint Surg. 1978;60 B (2): 270-5.
120. Seligson D, Popham GJ, Voos K, Henry SL, Faghri M. Antibioticleaching from polymethylmethacrylate beads. J Bone Joint Surg. 1993;75(5):714-20.
121. Arcos D, Ragel CV, Vallet-Regí M. Bioactivity in glass/PMMA composites used as drug delivery system. Biomaterials. 2001;22(7):701-8.
122. Vallet-Regí M, Arcos D, Pérez-Pariente J. Evolution of porosity during in vitro hydroxycarbonate apatite growth in sol-gel glasses. J Biomed Mater Res. 2000;51(1):23-8.
123. Zhang P, Hong Z, Yu T, Chen X, Jing X. In vivo mineralization and osteogenesis of nanocomposite scaffold of poly (lactide-coglycolide) and hydroxyapatite surface-grafted with poly (L-lactide). Biomaterials. 2009;30(1):58-70.
124. Katanec D, Pavelić B, Ivasović Z. Efficiency of polylactide/polyglycolide copolymers bone replacements in bone defects healing measured by densitometry. Collegium antropologicum. 2004;28(1):331-6.
125. Bertoldi C, Zaffe D, Consolo U. Polylactide/polyglycolide copolymer in bone defect healing in humans. Biomaterials. 2008;29(12):1817-23.
126. ® composites with tailored pore structure for tissue engineering applications. Comp Sci Technol. 2003;63(16):2417-29.
127. Li H, Chang J. Preparation, characterization and in vitro release of gentamicin from PHBV/wollastonite composite microspheres. J Controlled Release. 2005;107(3):463-73.
128. Wu C, Zhu Y, Chang J, Zhang Y, Xiao Y. Bioactive inorganicmaterials/ alginate composite microspheres with controllable drug-delivery ability. J Biomedical Mater Res Part B Appl Biomater. 2010;94 B (1): 32-43.
129. Halder A, Mukherjee S, Sa B. Development and evaluation of polyethyleneimine-treated calcium alginate beads for sustained release of diltiazem. J Microencapsul. 2005;22(1):67-80.